Cargando…

Change in skeletal muscle mass is associated with hepatic steatosis in nonalcoholic fatty liver disease

The association between nonalcoholic fatty liver disease (NAFLD) and sarcopenia is known. We aimed to determine the association between skeletal muscle mass changes and NAFLD status. This retrospective single-center study analyzed patients who underwent health screening twice between November 2009 a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jo, Ik Hyun, Song, Do Seon, Chang, U Im, Yang, Jin Mo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10147659/ https://www.ncbi.nlm.nih.gov/pubmed/37117864 http://dx.doi.org/10.1038/s41598-023-34263-z

Ejemplares similares

Nonalcoholic fatty liver disease: molecular mechanisms for the hepatic steatosis
por: Koo, Seung-Hoi
Publicado: (2013)

Ezetimibe decreased nonalcoholic fatty liver disease activity score but not hepatic steatosis
por: Lee, Hyo Young, et al.
Publicado: (2019)

Nonalcoholic Fatty Liver Disease: Noninvasive Methods of Diagnosing Hepatic Steatosis
por: AlShaalan, Rasha, et al.
Publicado: (2015)

Hepatic Steatosis in Infancy: The Beginning of Pediatric Nonalcoholic Fatty Liver Disease?
por: McNelis, Kera, et al.
Publicado: (2021)

Sulforaphane Attenuates Nonalcoholic Fatty Liver Disease by Inhibiting Hepatic Steatosis and Apoptosis
por: Li, Jinwang, et al.
Publicado: (2021)

The Association between Nonalcoholic Fatty Liver Disease and CT-Measured Skeletal Muscle Mass
por: Choe, Eun Kyung, et al.
Publicado: (2018)

Lipopolysaccharides accelerate hepatic steatosis in the development of nonalcoholic fatty liver disease in Zucker rats
por: Fukunishi, Shinya, et al.
Publicado: (2014)

Quantitative ultrasound approaches for diagnosis and monitoring hepatic steatosis in nonalcoholic fatty liver disease
por: Pirmoazen, Amir M., et al.
Publicado: (2020)

Does Nonalcoholic Pancreatic Steatosis Always Correlate with Nonalcoholic Fatty Liver Disease?
por: Ulasoglu, Celal, et al.
Publicado: (2021)

The Role of Skeletal Muscle in Development of Nonalcoholic Fatty Liver Disease
por: Moon, Jun Sung, et al.
Publicado: (2013)

Association Between Skeletal Muscle Mass and Severity of Steatosis and Fibrosis in Non-alcoholic Fatty Liver Disease
por: Guo, Wen, et al.
Publicado: (2022)

Nonalcoholic Fatty Liver Disease Is Associated With Low Skeletal Muscle Mass in Overweight/Obese Youths
por: Pacifico, Lucia, et al.
Publicado: (2020)

Dynamics of hepatic steatosis resolution and changes in gut microbiome with weight loss in nonalcoholic fatty liver disease
por: Behari, Jaideep, et al.
Publicado: (2021)

Effect of a ketogenic diet on hepatic steatosis and hepatic mitochondrial metabolism in nonalcoholic fatty liver disease
por: Luukkonen, Panu K., et al.
Publicado: (2020)

Skeletal Muscle Dysfunction in the Development and Progression of Nonalcoholic Fatty Liver Disease
por: Altajar, Sarah, et al.
Publicado: (2020)

Noninvasive Serum Fibrosis Markers are Associated with Coronary Artery Calcification in Patients with Nonalcoholic Fatty Liver Disease
por: Song, Do Seon, et al.
Publicado: (2019)

Lactobacillus attenuates progression of nonalcoholic fatty liver disease by lowering cholesterol and steatosis
por: Lee, Na Young, et al.
Publicado: (2021)

Severity of Liver Fibrosis Is Associated with the Japanese Diet Pattern and Skeletal Muscle Mass in Patients with Nonalcoholic Fatty Liver Disease
por: Matsumoto, Yoshinari, et al.
Publicado: (2023)

Relationship between Controlled Attenuation Parameter and Hepatic Steatosis as Assessed by Ultrasound in Alcoholic or Nonalcoholic Fatty Liver Disease
por: Ahn, Jem Ma, et al.
Publicado: (2016)

Herbicide Widespread: The Effects of Pethoxamid on Nonalcoholic Fatty Liver Steatosis In Vitro
por: Pirozzi, Anna Virginia Adriana, et al.
Publicado: (2020)

Low Skeletal Muscle Mass Is a Risk Factor for Subclinical Atherosclerosis in Patients with Nonalcoholic Fatty Liver Disease
por: Kang, Min-Kyu, et al.
Publicado: (2021)

The role of hepatic macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
por: Cha, Ji-Young, et al.
Publicado: (2018)

Andrographolide ameliorates hepatic steatosis by suppressing FATP2-mediated fatty acid uptake in mice with nonalcoholic fatty liver disease
por: Ran, Li-Sha, et al.
Publicado: (2022)

Silencing of FABP1 ameliorates hepatic steatosis, inflammation, and oxidative stress in mice with nonalcoholic fatty liver disease
por: Mukai, Takako, et al.
Publicado: (2017)

Therapeutic Effects of Garlic on Hepatic Steatosis in Nonalcoholic Fatty Liver Disease Patients: A Randomized Clinical Trial
por: Soleimani, Davood, et al.
Publicado: (2020)

The p66shc-mediated Regulation of Hepatocyte Senescence Influences Hepatic Steatosis in Nonalcoholic Fatty Liver Disease
por: Zhang, Jing, et al.
Publicado: (2020)

Relationship between relative skeletal muscle mass and nonalcoholic fatty liver disease: a systematic review and meta-analysis
por: Cai, Changzhou, et al.
Publicado: (2019)

Toyocamycin attenuates free fatty acid-induced hepatic steatosis and apoptosis in cultured hepatocytes and ameliorates nonalcoholic fatty liver disease in mice
por: Takahara, Ikuko, et al.
Publicado: (2017)

Noninvasive serum biomarkers for liver steatosis in nonalcoholic fatty liver disease: Current and future developments
por: Ahn, Sang Bong
Publicado: (2023)

Capybara Oil Improves Hepatic Mitochondrial Dysfunction, Steatosis, and Inflammation in a Murine Model of Nonalcoholic Fatty Liver Disease
por: Marinho, Polyana C., et al.
Publicado: (2018)

Erratum: The p66shc-Mediated Regulation of Hepatocyte Senescence Influences Hepatic Steatosis in Nonalcoholic Fatty Liver Disease
por: Zhang, Jing, et al.
Publicado: (2020)

Effects of Metformin on Hepatic Steatosis in Adults with Nonalcoholic Fatty Liver Disease and Diabetes: Insights from the Cellular to Patient Levels
por: Pinyopornpanish, Kanokwan, et al.
Publicado: (2021)

Association of Hepatic Steatosis Index with Nonalcoholic Fatty Liver Disease Diagnosed by Non-Enhanced CT in a Screening Population
por: Chung, Jieun, et al.
Publicado: (2021)

IκBζ regulates the development of nonalcoholic fatty liver disease through the attenuation of hepatic steatosis in mice
por: Ishikawa, Hideki, et al.
Publicado: (2022)

Quinoa Ameliorates Hepatic Steatosis, Oxidative Stress, Inflammation and Regulates the Gut Microbiota in Nonalcoholic Fatty Liver Disease Rats
por: Zhong, Lingyue, et al.
Publicado: (2023)

Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF-κB signaling pathways
por: Lee, Seung Min, et al.
Publicado: (2022)

Metabolic dysfunction is associated with steatosis but no other histologic features in nonalcoholic fatty liver disease
por: Dai, Yi-Ning, et al.
Publicado: (2022)

Discrepancies between Nonalcoholic and Metabolic-associated Fatty Liver Disease by Multiple Steatosis Assessment
por: Shao, Congxiang, et al.
Publicado: (2022)

Correction: Toyocamycin attenuates free fatty acid-induced hepatic steatosis and apoptosis in cultured hepatocytes and ameliorates nonalcoholic fatty liver disease in mice
por: Takahara, Ikuko, et al.
Publicado: (2020)

Exenatide ameliorates hepatic steatosis and attenuates fat mass and FTO gene expression through PI3K signaling pathway in nonalcoholic fatty liver disease
por: Li, Shan, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_dt3ng58v3re5dhq1dg00fj4o2p